Solubilization of Bifonazole in the Presence of Carboxymethylated-β- Cyclodextrin

The innovative technologies in the chemical and food industries
Proceedings of the 2nd International Scientific Conference «Chemical Technology and Engineering»: June 24–28, 2019, Lviv: Lviv Polytechnic National University, 2018, pp. 198–200

Authors

First and Last Name Academic degree E-mail Affiliation
Sergii Riabov Sc.D. Sergii.Riabov [at] gmail.com Institute of Macromolecular Chemistry the National Academy of Sciences of Ukraine
Kyiv, Ukraine
Larisa Kobrina Ph.D. kobrina.larisa [at] gmail.com of Macromolecular Chemistry the National Academy of Sciences of Ukraine
Kyiv, Ukraine
Sеrgii Sinelnikov Ph.D. sintsergey [at] gmail.com Institute of Macromolecular Chemistry the National Academy of Sciences of Ukraine
Kyiv, Ukraine
Daria Bandurina No lynx9999999 [at] gmail.com Nikolai Gogol State University of Nizhyn
Nizhyn, Ukraine

I and my co-authors (if any) authorize the use of the Paper in accordance with the Creative Commons CC BY license

First publshed on this website: 13.03.2019 - 21:16
Abstract

Recently, many technological methods of enhancing the solubility and dissolution characteristics of poorly water soluble drugs have been reported in the literature. Сyclodextrins are able to form water-soluble non-covalent inclusion complexes with many poorly soluble lipophilic drugs. The purpose of this study is to evaluate the possibility of interaction of the antifungal drug Bifonazole (BFZ) through complexation with carboxymethylated-β-cyclodextrin (КМ-β-CD). Based on the data obtained, we can conclude that the presence of KM-β-CD improves solubilization of BFZ more than 50 times.

References

[1] A. H. Al-Marzouqi, H. M. Elwy, I. Shehadi, A. Adem, “Physicochemical properties of antifungal drug–cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques,” Journal of Pharmaceutical and Biomedical Analysis, vol.49, no.2, Nov., pp. 227–233, 2009.

[2] R. G. Strickley, “Solubilizing excipients in oral and injectable formulations,”Pharmaceutical research, vol. 21, no. 2, pp. 201-230, Nov., 2004.

[3] T. Loftsson, M. Masson, M. E. Brewster, “Self-association of cyclodextrins and cyclodextrin complexes,” Journal of pharmaceutical sciences, vol.93, no 5, Feb., pp. 1091-1099, 2004.

[4] T. E. Lackner, S. P. Clissold, “Bifonazole. A Review of its antimicrobial activity and therapeutic use in superficial mycoses,” Drugs, vol.38, no. 2, August, pp. 204–225, 1989.

[5] D. Berg, K. H. Büchel, M. Plempel, E. Regel, “Antimycotic sterol biosynthesis inhibitors,”Trends in Pharmacology Sciences, vol.7, June, pp. 233–238, 1986.

[6] H. Petri, H. Tronnier, P. Haas, “Investigations into the antiinflammatory effect of bifonazole,” In: Hay R. J. (ed.). Advances in Topical Antifungal Therapy, Springer Verlag, Berlin, pp. 26–31, 1986.

[7] L. Hegemann, S. M. Toso, K. I. Lahijani, G. F. Webster, J. Ditto, “Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity,” Journal of Investigative Dermatology, vol.100, no. 3, Dec., pp. 343–346, 1993.

[8] H. Kelemen, A. Csillag, G. Hancu, B. Székely-Szentmiklósi, I. Fülöp, E. Varga, L. Grama, G. Orgován, “Characterization of inclusion complexes between bifonazole and different cyclodextrins in solid and solution state,” J. Chem. Chem. Eng., vol. 36 , no. 1, January, pp. 81–9, 2017.

Official paper